title: Sean Ekins on the Dangers of AI Drug Discovery
original_url: '"https://zencastr.com/z/0GgoC5K1"'
date_published: '2023-01-05'
host:
  name: Gus Ducker
  affiliation: Future of Life Institute
guests:
- name: Sean Ekins
  affiliation: Collaborations Pharmaceuticals
  title: Pharmacologist
  bio: Sean Ekins is a pharmacologist with expertise in computational toxicology and
    AI applications in drug discovery.
  expertise_areas:
  - Drug discovery
  - Computational toxicology
  - Artificial intelligence in pharmaceuticals
synopsis: In this episode, Sean Ekins discusses the transformative impact of AI on
  drug discovery and the associated risks, particularly regarding misuse in the creation
  of dangerous substances like chemical weapons. The conversation explores the evolution
  of computational methods in pharmaceuticals and the ethical implications of cutting-edge
  technologies.
key_topics:
- AI in drug discovery
- Computational toxicology
- Ethics in AI application
- Dual-use technologies
- Toxicology data sharing
tags:
- AI
- Drug Discovery
- Toxicology
- Ethics
key_points:
- AI has the potential to reduce reliance on animal testing.
- Access to large datasets can improve drug discovery outcomes.
- There are significant ethical concerns regarding the misuse of AI technologies.
- Pre-competitive data sharing is crucial for advancing research.
segments:
- title: Introduction to AI in Drug Discovery
  summary: Sean Ekins outlines his background and how AI has influenced his career
    in drug discovery, emphasizing the development of computational methods.
  key_quotes:
  - quote: '"I started to use computational approaches for drug discovery, and it''s
      influenced my whole career since that moment."'
    speaker: Sean Ekins
    context: Discussing his 25 years of experience in the field.
- title: Reducing Animal Testing with AI
  summary: Sean explains how AI can help minimize the use of animals in drug testing
    by simulating results using human data.
  key_quotes:
  - quote: '"If you can do a lot of the simulations in a computer, you''ve removed
      animals altogether."'
    speaker: Sean Ekins
    context: Talking about the benefits of computational toxicology.
- title: Risks of AI Misuse
  summary: The conversation delves into the risks involved with using AI in drug development,
    including the potential for designing harmful substances.
  key_quotes:
  - quote: '"We hadn''t previously thought about the risks, if I''m honest."'
    speaker: Sean Ekins
    context: Reflecting on the thought experiment regarding AI misuse.
- title: Ethical Considerations in AI Development
  summary: Sean discusses the ethical implications of AI technologies and the importance
    of training scientists to avoid dual-use scenarios.
  key_quotes:
  - quote: There needs to be some responsibility... to think about the potential for
      misuse.
    speaker: Sean Ekins
    context: Emphasizing the need for ethical training in using AI.
websites_referenced:
- url: '"https://pubchem.ncbi.nlm.nih.gov/"'
  name: PubChem
  context: A database housing large quantities of biological and toxicology data.
  access_date: '2023-01-05'
- url: '"https://kembel.org/"'
  name: Kembel Database
  context: A resource for toxicology and biological data.
  access_date: '2023-01-05'
tools_mentioned:
- name: Collaborations Pharmaceuticals
  url: ''
  description: A company focused on computational drug design for rare and neglected
    diseases.
  context: Sean Ekins founded this company to utilize AI in drug discovery.
research_papers:
- title: AI and Malicious AI in the context of chemical weapons
  authors:
  - Sean Ekins
  - Fabio Urbina
  - Philippa
  - Cedric
  year: 2023
  url: ''
  key_findings: The potential misuse of AI in designing chemical weapons is a serious
    concern that needs comprehensive guidelines and training for researchers.
  context: '"Published after a significant public response to initial findings on
    AI''s capabilities."'
books_referenced: []
organizations:
  academic_institutions:
  - name: Future of Life Institute
    location: Global
    context: Focuses on mitigating existential risks facing humanity, including those
      from advanced technologies.
  companies:
  - name: Collaborations Pharmaceuticals
    industry: Pharmaceuticals
    context: Develops computational approaches for drug discovery.
  non_profits: []
  government_agencies:
  - name: NIH (National Institutes of Health)
    country: USA
    context: Provided funding for technology development in drug discovery.
notable_people:
  academics: []
  industry_leaders:
  - name: Sean Ekins
    company: Collaborations Pharmaceuticals
    role: Pharmacologist
    context: Expert in AI applications in drug discovery.
  policy_makers: []
projects_mentioned:
- name: Kembel
  organization: ''
  description: A database for toxicology data among other biological datasets.
  status: Available
  url: '"https://kembel.org/"'
  context: Referenced as an important resource for data in drug discovery.
events:
  historical: []
  upcoming: []
keywords:
- AI drug discovery
- computational toxicology
- ethical AI
- dual-use technology
categories:
- Science
- Technology
- Ethics
intended_audience: Researchers and policymakers in drug discovery and AI ethics.
expertise_level: Intermediate
recommended_reading: []
action_items:
- Develop comprehensive guidelines for training on ethical AI use.
- Increase awareness of dual-use technologies among scientists.
controversial_topics:
- topic: Misuse of AI in drug discovery
  different_viewpoints:
  - perspective: AI can significantly benefit drug discovery.
    proponents: Many researchers in pharmaceuticals.
    key_arguments: AI minimizes animal testing, speeds up drug development, and utilizes
      large datasets.
  - perspective: AI poses risks of designing harmful substances.
    proponents: Critics of AI applications.
    key_arguments: Inadequate controls can lead to the creation of dangerous compounds,
      including chemical weapons.
